Ipsen Biopharmaceuticals, Inc.
1 Main Street
Unit 700
Cambridge
MA
02142
United States
Tel: 617-679-8500
Website: https://www.ipsenus.com/
Email: talentacquisition@ipsen.com
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
593 articles about Ipsen Biopharmaceuticals, Inc.
-
Approved in combination with three chemotherapies, Onivyde is the first new frontline treatment option in more than 10 years for adults living with metastatic pancreatic adenocarcinoma.
-
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
2/13/2024
Merrimack Pharmaceuticals, Inc. reported that Ipsen, SA issued a press release announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma.
-
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
2/8/2024
PARIS, FRANCE, 8 February 2024 - Ipsen, a global specialty-care biopharmaceutical company, presents its financial results for the year and final quarter of 2023.
-
Recent FDA approvals of novel drugs based on less-than-stellar clinical evidence point to a trend toward regulatory flexibility—particularly in indications with very high unmet need.
-
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
12/7/2023
Ipsen and GENFIT announced that the U.S. Food and Drug Administration has accepted the New Drug Application for investigational elafibranor.
-
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
12/7/2023
Ipsen, a global specialty-driven biopharmaceutical company, holds its Capital Markets Day in London, U.K.
-
In a late-stage trial, treatment with Ipsen and Genfit’s elafibranor led to high rates of biochemical response and the normalization of alkaline phosphatase levels compared with placebo.
-
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
11/13/2023
Ipsen and Medison Pharma are pleased to announce the Health Canada approval for Bylvay™ for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis, a progressive and life-threatening liver disease.
-
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
11/13/2023
Ipsen and GENFIT announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session at the American Association for the Study of Liver Diseases and simultaneously published in New England Journal of Medicine.
-
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
10/26/2023
Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the year to date and the third quarter of 2023.
-
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
8/21/2023
Exelixis, Inc. and Ipsen announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival at the primary analysis.
-
Boehringer Ingelheim will launch three Phase III studies for its obesity drug candidate; third time is a charm for Ipsen as it gets FDA approval; and Pfizer takes multiple myeloma battle to J&J.
-
After two prior setbacks, the regulator has finally approved Ipsen’s palovarotene to treat fibrodysplasia ossificans progressiva. It’s the first treatment for the ultra-rare bone disease.
-
The FDA has four decisions on deck this week, including ones for two rare disease treatments from Ipsen and Regeneron.
-
The first half of this year saw milestone approvals for rare disease therapies, and the FDA has several more such decisions on its calendar in the second half of 2023.
-
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
7/27/2023
Ipsen, a global specialty-care biopharmaceutical company, presents its financial results for the first half of 2023.
-
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
7/21/2023
Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) aged six months or older.
-
The companies Friday reported positive late-stage results for elafibranor as a second-line treatment for primary biliary cholangitis, a rare liver disease.
-
An FDA advisory committee voted Wednesday that Ipsen’s fibrodysplasia ossificans progressive candidate palovarotene was effective and the benefits of the drug outweighed its risks.
-
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
6/29/2023
Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effective treatment, with a positive risk-benefit profile, for people living with the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP).